- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Recently Accepted Articles ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Journal of Biomedicine and Biotechnology
Volume 2010 (2010), Article ID 294389, 6 pages
Cytokines and Their STATs in Cutaneous and Visceral Leishmaniasis
1Department of Microbiology, The Ohio State University, 484 West 12th Avenue, Columbus, OH 43210, USA
2Center for Microbial Interface Biology, The Ohio State University, 484 West 12th Avenue, Columbus, OH 43210, USA
Received 9 September 2009; Accepted 18 November 2009
Academic Editor: Luis I. Terrazas
Copyright © 2010 Hannah E. Cummings et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- The Center for Disease Control, “Parasites and health: leishmaniasis,” 2008, http://www.dpd.cdc.gov/dpdx/HTML/Leishmaniasis.htm.
- B. L. Herwaldt, “Leishmaniasis,” The Lancet, vol. 354, no. 9185, pp. 1191–1199, 1999.
- F. J. Tapia, G. Cáceres-Dittmar, and M. A. Sánchez, Molecular and Immune Mechanisms in the Pathogenesis of Cutaneous Leishmaniasis, R. G. Landes, Austin, Tex, USA, 1996.
- D. Sacks and A. Sher, “Evasion of innate immunity by parasitic protozoa,” Nature Immunology, vol. 3, no. 11, pp. 1041–1047, 2002.
- L. E. Rosas, T. Keiser, J. Barbi, et al., “Genetic background influences immune responses and disease outcome of cutaneous L. mexicana infection in mice,” International Immunology, vol. 17, no. 10, pp. 1347–1357, 2005.
- J. Alexander, A. R. Satoskar, and D. G. Russell, “Leishmania species: models of intracellular parasitism,” Journal of Cell Science, vol. 112, no. 18, pp. 2993–3002, 1999.
- S. Stäger, J. Alexander, K. C. Carter, F. Brombacher, and P. M. Kaye, “Both interleukin-4 (IL-4) and IL-4 receptor signaling contribute to the development of hepatic granulomas with optimal antileishmanial activity,” Infection and Immunity, vol. 71, no. 8, pp. 4804–4807, 2003.
- J. Alexander, K. Christine Carter, N. Al-Fasi, A. Satoskar, and F. Brombacher, “Endogenous IL-4 is necessary for effective drug therapy against visceral leishmaniasis,” European Journal of Immunology, vol. 30, no. 10, pp. 2935–2943, 2000.
- P. Tripathi, V. Singh, and S. Naik, “Immune response to leishmania: paradox rather than paradigm,” FEMS Immunology and Medical Microbiology, vol. 51, no. 2, pp. 229–242, 2007.
- D. Sacks and N. Noben-Trauth, “The immunology of susceptibility and resistance to Leishmania major in mice,” Nature Reviews Immunology, vol. 2, no. 11, pp. 845–858, 2002.
- J. Alexander and K. Bryson, “T helper (h)1/Th2 and Leishmania: paradox rather than paradigm,” Immunology Letters, vol. 99, no. 1, pp. 17–23, 2005.
- S. G. Reed, “TGF- in infections and infectious diseases,” Microbes and Infection, vol. 1, no. 15, pp. 1313–1325, 1999.
- P. Kroof, S. Herath, V. Weber, M. Modolell, and I. Müller, “Factors influencing Leishmania major infection in IL-4-deficint BALB/c mice,” Parasite Immunology, vol. 25, no. 8-9, pp. 439–447, 2003.
- L. R. Castellano, D. C. Filho, L. Argiro, et al., “Th1/Th2 immune responses are associated with active cutaneous leishmaniasis and clinical cure is associated with strong interferon- production,” Human Immunology, vol. 70, no. 6, pp. 383–390, 2009.
- L. U. Buxbaum and P. Scott, “Interleukin 10- and Fc receptor-deficient mice resolve Leishmania mexicana lesions,” Infection and Immunity, vol. 73, no. 4, pp. 2101–2108, 2005.
- B. N. Thomas and L. U. Buxbaum, “FcRIII mediates immunoglobulin G-induced interleukin-10 and is required for chronic Leishmania mexicana lesions,” Infection and Immunity, vol. 76, no. 2, pp. 623–631, 2008.
- A. L. Wurster, T. Tanaka, and M. J. Grusby, “The biology of Stat4 and Stat6,” Oncogene, vol. 19, no. 21, pp. 2577–2584, 2000.
- N. G. Jacobson, S. J. Szabo, R. M. Weber-Nordt, et al., “Interleukin 12 signaling in T helper type 1 (Th1) cells involves tyrosine phosphorylation of signal transducer and activator of transcription (Stat)3 and Stat4,” Journal of Experimental Medicine, vol. 181, no. 5, pp. 1755–1762, 1995.
- L. E. Rosas, H. M. Snider, J. Barbi, et al., “Cutting edge: STAT1 and T-bet play distinct roles in determining outcome of visceral leishmaniasis caused by Leishmania donovani,” Journal of Immunology, vol. 177, no. 1, pp. 22–25, 2006.
- J. Bromberg and J. E. Darnell Jr., “The role of STATs in transcriptional control and their impact on cellular function,” Oncogene, vol. 19, no. 21, pp. 2468–2473, 2000.
- D. J. Ghosh, D. E. Levy, R. W. Johnstone, and C. J. Clarke, “IFN signaling- does it mean JAK-STAT?” Cytokine & Growth Factor Reviews, vol. 19, no. 5-6, pp. 282–394, 2008.
- D. M. Mosser and J. P. Edwards, “Exploring the full spectrum of macrophage activation,” Nature Reviews Immunology, vol. 8, no. 12, pp. 958–969, 2008.
- K. Imada and W. J. Leonard, “The Jak-STAT pathway,” Molecular Immunology, vol. 37, no. 1-2, pp. 1–11, 2000.
- L. E. Rosas, T. Keiser, R. Pyles, J. Durbin, and A. R. Satoskar, “Development of protective immunity against cutaneous leishmaniasis is dependent of STAT1-mediated IFN signaling pathway,” European Journal of Immunology, vol. 33, no. 7, pp. 1799–1805, 2003.
- H. Bowen, A. Kelly, T. Lee, and P. Lavender, “Control of cytokine gene transcription in Th1 and Th2 cells,” Clinical and Experimental Allergy, vol. 38, no. 9, pp. 1422–1431, 2008.
- J. Barbi, H. M. Snider, N. Bhardwaj, C.M. Lezama-Dávila, J. E. Durbin, and A. R. Satoskar, “Signal transducer and activator of transcription 1 in T cells plays an indispensable role in immunity to Leishmania major by mediating Th1 cell homing to the site of infection,” The FASEB Journal, vol. 23, no. 11, pp. 3990–3999, 2009.
- J. Barbi, S. Oghumu, C. M. Lezama-Davila, and A. R. Satoskar, “IFN- and STAT1 are required for efficient induction of CXC chemokine receptor 3 (CXCR3) on but not T cells,” Blood, vol. 110, no. 6, pp. 2215–2216, 2007.
- L. E. Rosas, J. Barbi, B. Lu, et al., “CXCR3-/- mice mount an efficient Th1 response but fail to control Leishmania major infection,” European Journal of Immunology, vol. 35, no. 2, pp. 515–523, 2005.
- L. M. Johnson and P. Scott, “STAT1 expression in dendritic cells, but not T cells, is required for immunity to Leishmania major,” Journal of Immunology, vol. 178, no. 11, pp. 7259–7266, 2007.
- A. Diefenbach, H. Schindler, N. Donhauser, et al., “Type I interferons (IFN/) and type 2 nitric oxide synthase regulate the innate immune response to a protozoan parasite,” Immunity, vol. 8, no. 1, pp. 77–87, 1998.
- L. Xin, K. Li, and L. Soong, “Down-regulation of dendritic cell signaling pathways by Leishmania amazonensis amastigotes,” Molecular Immunology, vol. 45, no. 12, pp. 3371–3382, 2008.
- G. Trinchieri, “Interleukin-12 and the regulation of innate resistance and adaptive immunity,” Nature Reviews Immunology, vol. 3, no. 2, pp. 133–146, 2003.
- W. T. Watford, B. D. Hissong, J. H. Bream, Y. Kanno, L. Muul, and J. J. O'Shea, “Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4,” Immunological Reviews, vol. 202, pp. 139–156, 2004.
- M. A. McDowell and D. L. Sacks, “Inhibition of host cell signal transduction by Leishmania: observations relevant to the selective impairment of IL-12 responses,” Current Opinion in Microbiology, vol. 2, no. 4, pp. 438–443, 1999.
- A. R. Satoskar, S. Rodig, S. R. Telford III, et al., “IL-12 gene-deficient C57BL/6 mice are susceptible to Leishmania donovani but have diminished hepatic immunopathology,” European Journal of Immunology, vol. 30, no. 3, pp. 834–839, 2000.
- M. Rodriguez-Sosa, G. M. Monteforte, and A. R. Satoskar, “Susceptibility to Leishmania mexicana infection is due to the inability to produce IL-12 rather than lack of IL-12 responsiveness,” Immunology and Cell Biology, vol. 79, no. 4, pp. 320–322, 2001.
- K. Nelms, H. Huang, J. Ryan, A. Keegan, and W. E. Paul, “The IL-4 receptor: signaling mechanisms and biological functions,” Advances in Experimental Medicine and Biology, vol. 452, pp. 37–43, 1998.
- D. Hebenstreit, G. Wirnsberger, J. Horejs-Hoeck, and A. Duschl, “Signaling mechanisms, interaction partners, and target genes of STAT6,” Cytokine and Growth Factor Reviews, vol. 17, no. 3, pp. 173–188, 2006.
- A. Satoskar, H. Bluethmann, and J. Alexander, “Disruption of the murine interleukin-4 gene inhibits disease progression during Leishmania mexicana infection but does not increase control of Leishmania donovani infection,” Infection and Immunity, vol. 63, no. 12, pp. 4894–4899, 1995.
- C. R. Engwerda, S. C. Smelt, and P. M. Kaye, “An in vivo analysis of cytokine production during Leishmania donovani infection in scid mice,” Experimental Parasitology, vol. 84, no. 2, pp. 195–202, 1996.
- M. E. Wilson, B. M. Young, B. L. Davidson, K. A. Mente, and S. E. McGowan, “The importance of TGF- in murine Visceral leishmaniasis,” Journal of Immunology, vol. 161, no. 11, pp. 6148–6155, 1998.
- S. Stäger, J. Alexander, A. C. Kirby, et al., “Natural antibodies and complement are endogenous adjuvants for vaccine-induced T-cell responses,” Nature Medicine, vol. 9, no. 10, pp. 1287–1292, 2003.
- L. U. Buxbaum, “A detrimental role for IgG and FcgammaR in Leishmania mexicana infection,” Immunologic Research, vol. 42, no. 1-3, pp. 197–209, 2008.
- S. Bhowmick, T. Mazumdar, and N. Ali, “Vaccination route that induces transforming growth factor production fails to elicit protective immunity against Leishmania donovani infection,” Infection and Immunity, vol. 77, no. 4, pp. 1514–1523, 2009.
- M. L. Murphy, U. Wille, E. N. Villegas, C. A. Hunter, and J. P. Farrell, “IL-10 mediates susceptibility to Leishmania donovani infection,” European Journal of Immunology, vol. 31, no. 10, pp. 2848–2856, 2001.
- H. W. Ghalib, M. R. Piuvezam, Y. A. W. Skeiky, et al., “Interleukin 10 production correlates with pathology in human Leishmania donovani infections,” Journal of Clinical Investigation, vol. 92, no. 1, pp. 324–329, 1993.
- D. Nandan and N. E. Reiner, “Leishmania donovani engages in regulatory interference by targeting macrophage protein tyrosine phosphatase SHP-1,” Clinical Immunology, vol. 114, no. 3, pp. 266–277, 2005.
- D. M. Mosser and X. Zhang, “Interleukin-10: new perspectives on an old cytokine,” Immunological Reviews, vol. 226, no. 1, pp. 205–218, 2008.
- K. Takeda, T. Tsuneyasuk, N. Yoshida, J. Takeda, T. Kishimoto, and S. Akira, “Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T-cell- specific stat3-deficient mice,” Journal of Immunology, vol. 161, no. 9, pp. 4652–4660, 1998.
- K. Takeda, B. E. Clausen, T. Kaisho, et al., “Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of STAT3 in macrophages and neutrophils,” Immunity, vol. 10, no. 1, pp. 39–49, 1999.